The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...

Specifically, in the PRRT-naive cohort, the ORR reached 60%, while 34.1% of patients showed stable disease. Combining these ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

The investigational oral KRAS G12D inhibitor VS-7375 (GFH375) has shown a promising early safety profile and preliminary antitumor activity in pretreated patients with advanced solid tumors harboring ...

Jaume Capdevila, MD, Vall d'Hebron Hospital, discusses the final analysis of the phase 3 COMPETE trial (NCT03049189). Data ...

Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of ...

An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...

A panelist discusses how proactive management of CRS and ICANS supports safe community use of DLL3-targeted therapy.

A panelist discusses how data from the DeLLphi-304 trial position tarlatamab as a potential new standard for relapsed ...

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid ...

A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell ...